Dose Escalation For INtraprostatic LEsions

External beam radiotherapy combined with androgen deprivation therapy is a standard treatment option for localized prostate cancer. The current standard involves delivering radiotherapy uniformly throughout the prostate gland in daily fractions, five days per week, for approximately four weeks. In this study, radiotherapy will be delivered using an ultra-hypofractionated approach in three larger fractions on alternating days over one week Multiparametric magnetic resonance imaging will be used to guide focal dose escalation to parts of the gland harboring tumor, which could potentially reduce the risk of cancer recurrence compared to standard dose of radiotherapy. The aim of this study is to confirm that this approach can be delivered safely, that is, with rates of urinary and bowel side effects at 1 year of follow-up that are not significantly greater than the current standard.

NCT Number	NCT05851547
Lead Sponsor	Ottawa Hospital Research Institute Collaborators: Knight Therapeutics (USA) Inc
Conditions	Prostatic Neoplasms
Enrollment	54 participants
Start Date	2023-11-23
Primary Completion	2027-06 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2024-01-05